Tenaya Therapeutics (TNYA) Depreciation & Amortization (CF) (2020 - 2026)

Tenaya Therapeutics has reported Depreciation & Amortization (CF) for 7 years, with the latest figure at $1.8 million in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 33.75% year-over-year to $1.8 million; the trailing twelve-month figure through Mar 2026 stood at $7.5 million (down 16.0% YoY), and the FY2025 full-year result was $8.4 million, changed 0.38% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $1.8 million, down from $1.8 million in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $2.7 million in Q1 2025, with the low at $966000.0 in Q1 2022.
• Average Depreciation & Amortization (CF) over 5 years is $2.0 million, with a median of $2.1 million recorded in 2024.
• Year-over-year, Depreciation & Amortization (CF) soared 179.76% in 2022 and plunged 33.75% in 2026.
• Tracing TNYA's Depreciation & Amortization (CF) over 5 years: stood at $2.1 million in 2022, then gained by 3.02% to $2.2 million in 2023, then dropped by 4.22% to $2.1 million in 2024, then retreated by 12.54% to $1.8 million in 2025, then retreated by 3.5% to $1.8 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $1.8 million (Q1 2026), $1.8 million (Q4 2025), and $1.9 million (Q3 2025), per Business Quant data.

Peer Comparison